Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Joint Resurfacing: Boom or Bust?

Executive Summary

One of the hottest topics at the 2007 AAOS was the the trend toward resurfacing rather than completely replacing joints damaged by arthritis and other causes. There are a variety of metallic, synthetic and biologic methods used in hip, knee, shoulder and extremity joint resurfacing, many designed for younger patients who wish to remain active and avoid total joint replacement.

You may also be interested in...



Is Wright Medical Back on Track?

Wright Medical hasn’t enjoyed the smoothest ride over the past 15 years, a stretch that included a spin-out, debt problems, and a buyout, as well as an IPO. All the while, though, the company has proven to be an innovator in the large joints industries and now—under new CEO Gary Henley—it is establishing itself as a force in the extremities and biomaterials markets.

Is Wright Medical Back on Track?

Wright Medical hasn’t enjoyed the smoothest ride over the past 15 years, a stretch that included a spin-out, debt problems, and a buyout, as well as an IPO. All the while, though, the company has proven to be an innovator in the large joints industries and now—under new CEO Gary Henley—it is establishing itself as a force in the extremities and biomaterials markets.

TJR Market: Pressure on All Fronts

Aging baby boomers spell good news for the $11 billion total joint replacement industry. The bad news is the economic burden this highly active population, the major recipients of joint replacement surgeries, will place on the nation's health care system. With the number of TJR procedures expected to soar in the coming years, it's no surprise that CMS is focused on reducing the costs of TJR procedures. And that's bad news for the orthopedic surgeons who perform them.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel